RX Biosyent Inc

BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) released today a summary of its
Fiscal 2012 and Fourth Quarter (Q4) 2012 financial results. Key highlights
include:




--  Full year 2012 Sales of $5,024,154 increased 79% versus 2011 
--  Revenue has grown at a compound annual growth rate of 70% over the last
    three years 
--  Net Income before Tax margin increased to 28% in 2012 from 15% in 2011 
--  Full year 2012 Net Income after Tax of $1,541,317 increased 267%
    compared to 2011 
--  2012 represented the 3rd consecutive year of profitability for the
    Company 
--  2012 was the first year the Company paid income tax 
--  EPS (Basic) was $0.12 
--  The Company ended 2012 with $2,509,278 of working capital including
    $2,316,055 of cash 
--  The Company remains debt-free and has an unutilized operating line of
    credit with Royal Bank of Canada 
--  Selected as a TSX Venture 50 Top Performer for two consecutive years -
    2012 and 2013



Total sales for Q4 2012 of $1,327,953, were 89% higher compared to $703,337 in
the corresponding prior year period. On a full year basis, sales in 2012 of
$5,024,154 were 79% higher than the previous year sales of $2,808,666.


Net Income Before Tax for the fourth quarter of 2012 was $361,237 which is 454%
higher than $65,220 in the fourth quarter of 2011. Net Income Before Tax for
full year 2012 was $1,399,122 or 233% higher than $420,392 in corresponding
prior year 2011. The Net Income before Tax margin increased to 28% in 2012 from
15% in 2011. The Company has chosen to use Net Income Before Tax as a key
measure of performance as it is independent of tax fluctuations that might occur
due to the utilization of carried forward loses from previous years or changes
in tax rates.


The Company has provided for an income tax liability of $90,004 for the fourth
quarter of 2012, for the first time. The Company has also recognized a deferred
tax credit for the first time - $232,199, arising mainly from accumulated losses
carried forward from previous years while correspondingly recognizing a deferred
tax asset of like value on its consolidated statements of financial position.
The full year 2012 Net Income after Tax (NIAT) of $1,541,317 increased 267%
compared to $420,392 in 2011. Without the one-time recognition of the deferred
tax credit, Net Income after Tax for full year 2012 would have been $1,309,118.
The Total Comprehensive Income of $1,539,317 for 2012 was 268% higher than that
of $417,950 in 2011. Earnings per share (EPS) for full year 2012 were $0.12
Basic and $0.11 Diluted compared to $0.03 Basic and $0.03 Diluted in 2011.


Working capital, which is the difference between current assets and current
liabilities, has increased by 122% from $1,128,065 as at December 31, 2011 to $
2,509,278 as at December 31, 2012. Cash and cash equivalents on December 31,
2012 of $2,316,055 were 92% of working capital compared to 94% as at December
31, 2011. Cash Generation, or the increase in Cash and Cash Equivalents, of
$1,258,009 in 2012, represents a 114% increase over $586,951 in the prior year
period.


The Financial Statements and Management's Discussion & Analysis will be posted
on www.sedar.com on March 21, 2012. The launch of FeraMAX(R) Powder has been
delayed due to scale-up of production.


For a direct market quote (15 minutes delay) for the TSX Venture Exchange and
other Company financial information please visit www.tmxmoney.com.


About BioSyent Inc.

Listed on the Toronto Venture Exchange under the trading symbol "RX", BioSyent
is a profitable growth oriented specialty pharmaceutical company which searches
the globe to in-license or acquire innovative pharmaceutical products that have
been successfully developed, are safe and effective, and have a proven track
record of improving the lives of patients and supporting the healthcare
professionals that treat them.


Once a product of interest has been found, BioSyent then acquires the exclusive
rights to the product and manages it through the Canadian governmental
regulatory approval process. Once approved, BioSyent markets the product
throughout Canada. 


At the date of this press release the Company had 13,271,195 shares issued and
outstanding. 


This press release may contain information or statements that are
forward-looking. The contents herein represent our judgment, as at the release
date, and are subject to risks and uncertainties that may cause actual results
or outcomes to be materially different from the forward-looking information or
statements. Potential risks may include, but are not limited to, those
associated with clinical trials, product development, future revenue,
operations, profitability and obtaining regulatory approvals.


FOR FURTHER INFORMATION PLEASE CONTACT: 
BioSyent Inc.
Mr. Rene C. Goehrum
President and CEO
(905) 206-0013
investors@biosyent.com
www.biosyent.com

Biosyent (TSXV:RX)
Historical Stock Chart
From May 2024 to Jun 2024

Biosyent (TSXV:RX)
Historical Stock Chart
From Jun 2023 to Jun 2024